MedTrace Logo

A Trial of Varenicline for E-cigarette Cessation

NCT07040566 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2025-12-17

No results posted yet for this study

Summary

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

Conditions

  • E-cigarette Use
  • Vaping
  • Nicotine Dependence

Interventions

DRUG

Varenicline 1mg BID

12 weeks following the standard titration of 1 mg, twice daily

DRUG

Placebo

Matching placebo twice daily

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Lisa Fucito, PhD · Yale University

  • Benjamin Toll, PhD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2030-07-30
Completion
2030-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07040566 on ClinicalTrials.gov